Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Fate Therapeutics collapses 55% after terminating Janssen deal, earns several downgrades

Published 2023-01-06, 08:57 a/m
Updated 2023-01-06, 08:57 a/m
© Reuters.

© Reuters.

By Senad Karaahmetovic 

Shares of Fate Therapeutics (NASDAQ:FATE) are down more than 56% in pre-market after the company said it has declined a proposal from Janssen Biotech, which is owned by Johnson & Johnson (NYSE:JNJ), for the continuation of the collaboration and option agreement between the parties.

As a result, the agreement has been terminated and the FT596 product candidate is discontinued. Instead, the company plans to focus on its CD19-targeted CAR NK cell program.

"We are disappointed that we were not able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023," said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Fate added that it ended the fourth quarter with about $475 million in cash and is expected to have sufficient financial resources through the end of 2025.

The massive selloff in FATE stock has been accelerated by at least 8 downgrades following the announcement. Truist analysts downgraded to Hold with a $7 per share price target (down from the prior $46).

"In the near-term we remain on the sidelines as we await greater clarity on strategy, FDA feedback on how to move forward and timelines for data readouts from next-gen assets… In the longer-term, we see focus on nextgen as a smart move, and believe company has been telegraphing that for a while," the analysts wrote in a note.

BMO analysts cut the rating to Market Perform from Outperform as the prior buy thesis on the stock has now been challenged.

"While FATE's actions will help extend cash runway through 2025, we see limited opportunities for value generation near and medium-term and lack sufficient data pointing to competitive profiles from ongoing programs (ASH takeaways). As a result, we're removing discontinued programs from our model and downgrading to Market Perform," they said.

As of 08:28 GMT (13:28 GMT), FATE stock trades 56.36% lower.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.